Taysha Gene Therapies (TSHA) News Today $2.71 -0.04 (-1.45%) Closing price 04:00 PM EasternExtended Trading$2.66 -0.04 (-1.66%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is Taysha Gene Therapies Down Today?Taysha Gene Therapies, Inc. (NASDAQ: TSHA) shares are rising amid multiple bullish catalysts. Investors are reacting to the company’s detailed design for a pivotal Part B trial of its gene therapy candidate TSHA-102 in Rett Syndrome, strong clinical data from Part A, and a string of analyst upgrades and price-target hikes. Announced pivotal Part B trial design details for TSHA-102 in Rett Syndrome, leveraging IRSF natural history data and positive Part A clinical results Received FDA alignment on IND amendments needed to initiate the pivotal Part B study JMP Securities raised its price target on TSHA from $5.00 to $6.00 and assigned a “market outperform” rating Chardan Capital increased its price objective from $7.00 to $9.00 and maintained a “buy” rating American Banking News lifted its TSHA price target to $9.00 Shares gapped higher following the wave of analyst upgrades and target-price increases Global market for Rett Syndrome therapies in major markets is projected to reach $441.5 million by 2035, underscoring significant commercial upside Highlighted as a “stock to watch” by MarketWatch alongside other major tech and healthcare names These developments collectively support increased investor confidence in TSHA’s clinical progress and long-term growth potential in the Rett Syndrome space.Posted 47m agoAI Generated. May Contain Errors. TSHA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of ...May 30 at 2:59 PM | morningstar.comTaysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial DataMay 30 at 2:59 PM | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Analyst UpgradeMay 30 at 10:05 AM | marketbeat.comJMP Securities Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceJMP Securities raised their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday.May 30 at 10:02 AM | marketbeat.comChardan Capital Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceChardan Capital increased their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday.May 30 at 8:16 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $9.00May 30 at 3:19 AM | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Analyst UpgradeMay 30 at 1:49 AM | americanbankingnews.comTaysha: TSHA-102 Presses On With IND Part B Protocol And SAP AmendmentsMay 29 at 5:07 PM | seekingalpha.comTaysha stock surges on positive trial design and FDA alignmentMay 29 at 4:28 PM | investing.comStocks to Watch: Nvidia, HP, Taysha Gene TherapiesMay 29 at 11:27 AM | marketwatch.comTaysha Shares Jump 19% Following Favorable Trial Design and FDA Feedback for Rett Syndrome TherapyMay 29 at 11:27 AM | msn.comTaysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+May 29 at 12:57 AM | insidermonkey.comTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsMay 28 at 10:40 PM | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 28 at 4:02 PM | globenewswire.comTaysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102May 28 at 4:01 PM | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.57 Consensus PT from BrokeragesMay 28 at 2:39 AM | americanbankingnews.comReviewing Taysha Gene Therapies (NASDAQ:TSHA) & Quince Therapeutics (NASDAQ:QNCX)May 28 at 1:51 AM | americanbankingnews.comTaysha Gene Therapies’ SWOT analysis: promising gene therapy stock faces pivotal yearMay 27 at 9:05 PM | investing.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have earned an average recommendation of "Buy" from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12 montMay 26, 2025 | marketbeat.comRafferty Asset Management LLC Takes $436,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Rafferty Asset Management LLC bought a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 252,257 shares of the company's stock, valued atMay 25, 2025 | marketbeat.comFY2025 EPS Estimates for TSHA Increased by Cantor FitzgeraldTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Cantor Fitzgerald lifted their FY2025 EPS estimates for Taysha Gene Therapies in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.36) fMay 23, 2025 | marketbeat.comCantor Fitzgerald Has Positive View of TSHA FY2025 EarningsMay 23, 2025 | americanbankingnews.comVR Adviser LLC Sells 5,774,820 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)VR Adviser LLC reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 64.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,225,180 shares of the company's stock afterMay 22, 2025 | marketbeat.comRTW Investments LP Has $15 Million Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)RTW Investments LP cut its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 42.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,672,630 shares of the company's stock after sellingMay 18, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comQ1 2025 Taysha Gene Therapies Inc Earnings CallMay 16, 2025 | finance.yahoo.comTaysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ...May 16, 2025 | finance.yahoo.comTaysha Gene Therapies Advances in Rett Syndrome TrialsMay 16, 2025 | tipranks.comTaysha outlines expedited pivotal trial start for TSHA-102 following FDA alignmentMay 15, 2025 | msn.comTaysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comTaysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Bought by Octagon Capital Advisors LPOctagon Capital Advisors LP grew its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 128.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,450,000 shares of the company's stock after puMay 15, 2025 | marketbeat.comGranahan Investment Management LLC Buys 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Granahan Investment Management LLC lifted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 43.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,636,381 shares of the company's stock after purchaMay 13, 2025 | marketbeat.comDAFNA Capital Management LLC Makes New $904,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)DAFNA Capital Management LLC bought a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 522,500 shares of the company'sMay 10, 2025 | marketbeat.comTaysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15May 8, 2025 | globenewswire.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-taysha-gene-therapies-inc-stock/)May 8, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Marshall Wace LLP trimmed its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 71.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,111 shares of the companyMay 8, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9.3% - What's Next?Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.3% - What's Next?May 5, 2025 | marketbeat.comAcuta Capital Partners LLC Cuts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Acuta Capital Partners LLC cut its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 58.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 884,244 shares ofMay 4, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received an average rating of "Buy" from the eight ratings firms that are presently covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price objectiMay 2, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Makes New $8.65 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,000,000 shares of tMay 1, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)JMP Securities reiterated a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Monday.April 30, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday.April 30, 2025 | marketbeat.comRenaissance Technologies LLC Makes New $1.52 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Renaissance Technologies LLC purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 878,448 shares of the company's stock, valued at approxiApril 29, 2025 | marketbeat.comAvoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Avoro Capital Advisors LLC increased its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,999,999 shares of the company's stock after acquiring an addApril 23, 2025 | marketbeat.comB Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)B Group Inc. purchased a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 965,556 shares of the company's stock, valued at apprApril 23, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,643,755 shares of the company's stock afterApril 21, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Vanguard Group Inc. raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,906,764 shares of the company's stock after acquiringApril 20, 2025 | marketbeat.comTaysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited OpportunityApril 16, 2025 | seekingalpha.com Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Media Mentions By Week TSHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSHA News Sentiment▼0.910.88▲Average Medical News Sentiment TSHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSHA Articles This Week▼213▲TSHA Articles Average Week Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCM News AAPG News XENE News OGN News AMRX News IBRX News APLS News MIRM News ARWR News VCEL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSHA) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
